Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Open Access
- 12 November 2020
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (2) , 561-568
Abstract
Aim: To evaluate whether atrasentan plasma exposure explains between‐patient variability in urinary albumin‐to‐creatinine ratio (UACR) response, a surrogate for kidney protection, and B‐type natriuretic peptide (BNP) response, a surrogate for fluid expansion. Methods: Type 2 diabetic patients with chronic kidney disease (n = 4775) received 0.75 mg atrasentan for 6 weeks in the active run‐in period. Individual area under the concentration‐time‐curve (AUC) was estimated using a population pharmacokinetic model. The association between atrasentan AUC, other clinical characteristics, and UACR and BNP response, was estimated using linear regression. Results: The median atrasentan AUC was 43.8 ng.h/mL with a large variation among patients (2.5th‐97.5th percentiles [P]: 12.6 to 197.5 ng.h/mL). Median UACR change at the end of enrichment was −36.0% and median BNP change was 8.7%, which also varied among patients (UACR, 2.5th‐97.5th P: −76.2% to 44.5%; BNP, 2.5th‐97.5th P: −71.5% to 300.0%). In the multivariable analysis, higher atrasentan AUC was associated with greater UACR reduction (4.88% per doubling in ng.h/mL [95% confidence interval {CI}: 6.21% to 3.52%], P < .01) and greater BNP increase (3.08% per doubling in ng.h/mL [95% CI: 1.12% to 4.11%], P < .01) independent of estimated glomerular filtration rate, haemoglobin or BNP. Caucasian patients compared with black patients had greater UACR reduction (7.06% [95% CI: 1.38% to 13.07%]) and also greater BNP increase (8.75% [95% CI: 1.65% to 15.35%]). UACR response was not associated with BNP response (r = 0.06). Conclusion: Atrasentan plasma exposure varied among individual patients and partially explained between‐patient variability in efficacy and safety response.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (917.15.306)
- Novo Nordisk UK Research Foundation (NNF OC0013659)
This publication has 17 references indexed in Scilit:
- Comparison of exposure response relationship of atrasentan between N orth A merican and A sian populationsDiabetes, Obesity and Metabolism, 2016
- Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyClinical Journal of the American Society of Nephrology, 2015
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic NephropathyJournal of the American Society of Nephrology, 2014
- Interactive Influences of Ethnicity, Endothelin-1 Gene, and Everyday Discrimination Upon Nocturnal Ambulatory Blood PressureAnnals of Behavioral Medicine, 2013
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic NephropathyJournal of the American Society of Nephrology, 2011
- Avosentan for Overt Diabetic NephropathyJournal of the American Society of Nephrology, 2010
- Endothelin, hypertension and chronic kidney disease: new insightsCurrent Opinion in Nephrology and Hypertension, 2010
- Likelihood based approaches to handling data below the quantification limit using NONMEM VIJournal of Pharmacokinetics and Pharmacodynamics, 2008
- BNP and congestive heart failureProgress in Cardiovascular Diseases, 2002
- Increased Human Brain Natriuretic Peptide in Congestive Heart FailureNew England Journal of Medicine, 1990